Your session is about to expire
← Back to Search
NeuroVax for Multiple Sclerosis
Study Summary
This trial is studying a vaccine called NeuroVax to see if it is better than a placebo at treating people with secondary progressive multiple sclerosis.
- Multiple Sclerosis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What other medical tests have used NeuroVax as a primary treatment?
"There are two ongoing clinical trials evaluating the efficacy of NeuroVax. One is in Phase 3 and both are based out of California, with one being in San Diego and the other having an unknown location."
Who meets the requirements to participate in this experiment?
"This study is recruiting 200 individuals with multiple sclerosis that are between 18-50 years old. Most importantly, potential participants must meet the following conditions: Be diagnosed with MS using the revised McDonald criteria from 2005, have a secondary progressive course of the disease, an EDSS score of 3.5 or higher (Appendix B), have had two documented clinical relapses in MS in the past 24 months OR one relapse in the 12 months prior to screening , creatinine level 1 . 5x above normal, and hemoglobin levels within normal range."
Are we still looking for volunteers for this experiment?
"The clinical trial, which was posted on March 9th 2020 and last updated on the same day, is presently looking for patients according to information available on clinicaltrials.gov"
How many people are being treated as part of this clinical research?
"Yes, the trial is recruiting patients at this time. The original posting date was March 9th, 2020 and there have been no updates since then. They are looking for 200 participants from a single site."
Have other medical studies like this been conducted before?
"NeuroVax was first studied in 2020 by Immune Response BioPharma, Inc. The Phase 2 & 3 drug approval followed the initial study of 200 patients. As of now, there are two active clinical trials involving NeuroVax being conducted across one city and one nation."
Are people of all ages welcome in this clinical trial?
"This clinical trial has age restrictions of 18-50, as outlined in the inclusion criteria."
Share this study with friends
Copy Link
Messenger